Fracture of the calcium phosphate bone cement which used to enchondroma of the hand: a case report
- First Online:
- Cite this article as:
- Naito, K., Obayashi, O., Mogami, A. et al. Eur J Orthop Surg Traumatol (2008) 18: 405. doi:10.1007/s00590-008-0321-x
- 358 Downloads
Enchondroma of a hand is a common benign tumor. Enchondroma commonly presents as a pathological fracture associated with pain, deformity, and swelling. Dysfunction of the fingers occurs as a result of the fracture. Curettage is the mainstay of surgical treatment for enchondroma.
KeywordsEnchondromaCalcium phosphate bone cementBone conduction
Enchondroma of a hand is a common benign tumor. Enchondroma commonly presents as a pathological fracture associated with pain, deformity, and swelling. Dysfunction of the fingers occurs as a result of the fracture. Curettage is the mainstay of surgical treatment for enchondroma. The bone defect is then filled with bone chips and bone substitutes, such as calcium phosphate bone cement (CPC) and hydroxyapatite [1, 4–8]. We treated enchondroma of the 5th middle phalanx by curettage and filled the defect with CPC. However, fracture of CPC was caused by slight injury. Therefore, we removed this broken CPC and filled the defect with autologous bone graft. After 1 year, patient had achieved good functional and radiographic results.
A case report
Enchondromas are predominantly seen in the skeleton of the hand and are the most frequent osseous tumors of the hand. In treating enchondromas, surgeons aim to prevent pathological fracture and remove the tumor. There are numerous reports presenting results after operative treatment of enchondromas [1, 4–8]. Enchondromas are treated by curettage and the bone defect is then usually filled with morselized autologous bone chip from the iliac crest or with an allograft. Recently, bone substitutes, such as calcium phosphate bone cement (CPC) and hydroxyapatite, have also been used instead of autologous or allogenic bone grafts [1, 5, 6, 8].
It is well-known that a fresh fracture is surrounded by hematoma, and this hematoma will be invaded by multi-potent mesenchymal cells which differentiate into osteoblasts, a pre-requisite for bone healing . Therfeore, curettage has recently become the mainstay of surgical treatment for enchondroma. However, patients who have undergone curettage alone must restrict their activity with the operated hand. We treated our case by curettage and part of the bone defect was filled with CPC during the first operation, because this technique provides immediate mechanical stability and allows early mobilization and force transmission around the adjacent joint .
CPC offers advantages over polymethylmethacrylate (PMMA), such as eventual osseous resorption and euthermic consolidation reaction. In vitro, comparing the strength of CPC with that of PMMA in subchondral bone defects, CPC is stronger than PMMA . Regarding bone conduction, CPC is inferior to beta tricalcium phosphate (beta-TCP). Beta-TCP appeared to be a bone replacement material with optimal biocompatibility, resorption characteristics and bone conduction properties for clinical use . However, bone conduction dose not occur with CPC.
Yasuda et al. reported outcome of treating enchondroma of the hand by curettage and CPC grafting . The average follow-up period was 41 months that study. They considered CPC a good candidate for treatment of enchondroma of the hand.
The primary stability of CPC is very strong, however, there is no bone conduction of CPC. This is a limitation of using CPC as a bone substitute. Therefore, in our case, we think fracture of CPC was caused by a slight injury sustained 31 months post-operatively.
Conflict of interest statement
No funds were received in support of this study.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.